TY - JOUR
T1 - Recent Advances in the Treatment and Management of Relapsed/Refractory Multiple Myeloma
T2 - Expert Perspectives on the Role of New Therapies
AU - Vij, Ravi
N1 - Publisher Copyright:
© 2022 National Association of Managed Care Physicians, Inc.. All rights reserved.
PY - 2022
Y1 - 2022
N2 - New, more effective, and less toxic therapies have revolutionized the management of multiple myeloma in the past decade. Triple therapy with proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies is now the standard treatment. Despite the availability of new treatments, most patients will develop refractory disease to the therapies that currently comprise the standard of care.
AB - New, more effective, and less toxic therapies have revolutionized the management of multiple myeloma in the past decade. Triple therapy with proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies is now the standard treatment. Despite the availability of new treatments, most patients will develop refractory disease to the therapies that currently comprise the standard of care.
UR - http://www.scopus.com/inward/record.url?scp=85160564612&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85160564612
SN - 1094-1525
VL - 25
SP - 61
EP - 66
JO - Journal of Managed Care Medicine
JF - Journal of Managed Care Medicine
IS - 1
ER -